We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxford Biomedica Plc | LSE:OXB | London | Ordinary Share | GB00BDFBVT43 | ORD 50P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 3.50 | 1.63% | 218.50 | 217.50 | 219.00 | 225.00 | 216.50 | 218.00 | 275,918 | 16:35:12 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medicinal Chems,botanicl Pds | 139.99M | -45.16M | -0.4676 | -4.66 | 210.55M |
From Apr 2022 to Apr 2024
TIDMOXB
RNS Number : 1810K
Oxford Biomedica PLC
03 May 2022
Grant of options
London, UK - 03 May 2022: Oxford Biomedica plc ("Oxford Biomedica" or "the Company") (LSE: OXB) announces that on 29 April 2022 nil-cost share options over ordinary shares of 50 pence each in the Company were granted under the Oxford Biomedica 2015 Deferred Bonus Plan ("DBP") and the Oxford Biomedica 2015 Long Term Incentive Plan ("LTIP").
2022 LTIP and 2021 DBP Awards
Hot Features
Premium
Name of individual Title Number Number Total shares Percentage
of shares of shares over which of current
subject subject options issued share
to the to the now held capital
2021 DBP 2022 LTIP under option
award award
Chief Executive
Officer
until 28
January
John Dawson 2022 52,118 - 827,669 0.9%
------------------- ----------- ----------- ------------- --------------
Chief Financial
Stuart Paynter Officer 35,171 96,100 347,623 0.4%
------------------- ----------- ----------- ------------- --------------
Chief Commercial 5,082
Dave Backer Officer (1) 47,197 69,213 0.07%
------------------- ----------- ----------- ------------- --------------
Chief Executive
Officer
of OXB
Tim Kelly Solutions - 38,528 191,305 0.2%
------------------- ----------- ----------- ------------- --------------
Chief People
Lisa James Officer - 26,376 44,432 0.05%
------------------- ----------- ----------- ------------- --------------
Chief Technical
James Miskin Officer 16,168 38,135 181,357 0.2%
------------------- ----------- ----------- ------------- --------------
Kyriacos Chief Scientific
Mitrophanous Officer 16,321 38,501 198,510 0.2%
------------------- ----------- ----------- ------------- --------------
Nicholas Chief Operations
Page Officer 17,381 40,261 157,464 0.2%
------------------- ----------- ----------- ------------- --------------
Madduri Ravi Chief Medical
Rao Officer - 28,318 60,136 (2) 0.06%
------------------- ----------- ----------- ------------- --------------
Chief Business
Jason Slingsby Officer 15,458 36,466 129,188 0.1%
------------------- ----------- ----------- ------------- --------------
Chief Information
Matthew Treagus Officer 5,314 38,501 56,412 0.06%
------------------- ----------- ----------- ------------- --------------
General
Natalie Walter Counsel 14,008 32,268 102,858 0.1%
------------------- ----------- ----------- ------------- --------------
Chief of
Alex Lewis Staff - 9,423 (3) 78,650 0.08%
------------------- ----------- ----------- ------------- --------------
(1) Dave Backer's DBP award were granted under the 2015 LTIP scheme as opposed to the 2015 Deferred Bonus Plan (DBP) due to US tax considerations and California regulatory considerations.
(2) Dr. Madduri Rao's RSU joining options (see below) are included in this figure.
Under the terms of the DBP plan, the DBP awards will become exercisable as to one third of the shares subject to each award on each of the first three anniversaries of the grant date.
In line with best practice and current investor guidance the quantum of the 2022 LTIP to Stuart Paynter was scaled back from 175% of salary to 155% of salary. The quantum of 2022 LTIP granted to other members of SET was scaled back in line with Stuart Paynter's scale back percentage.
John Dawson did not received an award under the LTIP scheme for 2022.
The LTIP awards are subject to performance conditions. As set out in the 2021 Directors' Remuneration Report, the performance condition is based on TSR (40% of the award, assessed over the three years from grant); revenue growth (40% of the award, assessed over financial years 2022, 2023 and 2024) and strategic milestones (20% of the award). Details of the measures are included in the 2021 Directors' Remuneration Report, other than as regards the strategic milestones, which are commercially sensitive and will be disclosed in due course.
The LTIP awards granted Stuart Paynter will "vest" following the assessment of the performance condition, but will only be "released" so that they can be exercised following the end of a further two year holding period. The 2022 awards granted to other participants will vest and be released following the assessment of the performance condition.
RSU awards
(3) In addition, on 29 April 2022 a nil-cost share option over 9,423 shares of 50 pence each in the Company was also granted under the LTIP scheme to Alexander Lewis, Chief of Staff.
As joining shares, a nil-cost share option over 31,818 shares of 50 pence each in the Company was also granted under the LTIP scheme to Dr Madduri Rao.
The RSU awards are not subject to performance conditions and will become exercisable from the third anniversary of the grant date.
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
Notification of Dealing Form
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name John Dawson
----------------------------- --------------------------------------
2. Reason for the notification
---------------------------------------------------------------------
a) Position/status Chief Executive Officer
----------------------------- --------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- --------------------------------------
3. Details of the Issuer
---------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- --------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- --------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
---------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- --------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Deferred Bonus
Plan. No consideration was paid for
the grant of awards.
----------------------------- --------------------------------------
c) Price(s) and volumes(s) 2022 LTIP Award
Price Volume
Nil Nil
-------
2021 DBP Award
Price Volume
Nil 52,118
-------
----------------------------- --------------------------------------
d) Aggregated information Awards granted over 52,118 shares in
* Aggregate volume total
N/A
* Price
----------------------------- --------------------------------------
e) Date of the transaction 2022-04-29
----------------------------- --------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- --------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Stuart Paynter
----------------------------- ------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------------
a) Position/status Chief Financial Officer
----------------------------- ------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- ------------------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration
was paid for the grant of awards.
----------------------------- ------------------------------------------------
c) Price(s) and volumes(s) 2022 LTIP Award
Price Volume
Nil 96,100
-------
2021 DBP Award
Price Volume
Nil 35,171
-------
----------------------------- ------------------------------------------------
d) Aggregated information Awards granted over 131,271 shares
* Aggregate volume in total
N/A
* Price
----------------------------- ------------------------------------------------
e) Date of the transaction 2022-04-29
----------------------------- ------------------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- ------------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Dave Backer
----------------------------- ------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------------
a) Position/status Chief Commercial Officer
----------------------------- ------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- ------------------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration
was paid for the grant of awards.
----------------------------- ------------------------------------------------
c) Price(s) and volumes(s) 2022 LTIP Award
Price Volume
Nil 47,197
-------
2021 DBP Award
Price Volume
Nil 5,082
-------
----------------------------- ------------------------------------------------
d) Aggregated information Awards granted over 52,279 shares in
* Aggregate volume total
N/A
* Price
----------------------------- ------------------------------------------------
e) Date of the transaction 2022-04-29
----------------------------- ------------------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- ------------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Tim Kelly
----------------------------- -----------------------------------------
2. Reason for the notification
------------------------------------------------------------------------
a) Position/status Chief Executive Officer of OXB Solutions
----------------------------- -----------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------------
3. Details of the Issuer
------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- -----------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- -----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- -----------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan. No consideration was paid for
the grant of awards.
----------------------------- -----------------------------------------
c) Price(s) and volumes(s) 2022 LTIP Award
Price Volume
Nil 38,528
-------
2021 DBP Award
Price Volume
Nil Nil
-------
----------------------------- -----------------------------------------
d) Aggregated information Awards granted over 38,528 shares in
* Aggregate volume total
N/A
* Price
----------------------------- -----------------------------------------
e) Date of the transaction 2022-04-29
----------------------------- -----------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- -----------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Lisa James
----------------------------- -----------------------------------------
2. Reason for the notification
------------------------------------------------------------------------
a) Position/status Chief People Officer
----------------------------- -----------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------------
3. Details of the Issuer
------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- -----------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- -----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- -----------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan. No consideration was paid for
the grant of awards.
----------------------------- -----------------------------------------
c) Price(s) and volumes(s) 2022 LTIP Award
Price Volume
Nil 26,376
-------
2021 DBP Award
Price Volume
Nil Nil
-------
----------------------------- -----------------------------------------
d) Aggregated information Awards granted over 26,376 shares in
* Aggregate volume total
N/A
* Price
----------------------------- -----------------------------------------
e) Date of the transaction 2022-04-29
----------------------------- -----------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- -----------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name James Miskin
----------------------------- ------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------------
a) Position/status Chief Technical Officer
----------------------------- ------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- ------------------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration
was paid for the grant of awards.
----------------------------- ------------------------------------------------
c) Price(s) and volumes(s) 2022 LTIP Award
Price Volume
Nil 38,135
-------
2021 DBP Award
Price Volume
Nil 16,168
-------
----------------------------- ------------------------------------------------
d) Aggregated information Awards granted over 54,303 shares in
* Aggregate volume total
N/A
* Price
----------------------------- ------------------------------------------------
e) Date of the transaction 2022-04-29
----------------------------- ------------------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- ------------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Kyriacos Mitrophanous
----------------------------- ------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------------
a) Position/status Chief Scientific Officer
----------------------------- ------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- ------------------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration
was paid for the grant of awards.
----------------------------- ------------------------------------------------
c) Price(s) and volumes(s) 2022LTIP Award
Price Volume
Nil 38,501
-------
2021 DBP Award
Price Volume
Nil 16,321
-------
----------------------------- ------------------------------------------------
d) Aggregated information Awards granted over 54,822 shares in
* Aggregate volume total
N/A
* Price
----------------------------- ------------------------------------------------
e) Date of the transaction 2022-04-29
----------------------------- ------------------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- ------------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Nicholas Page
----------------------------- ------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------------
a) Position/status Chief Operations Officer
----------------------------- ------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- ------------------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration
was paid for the grant of awards.
----------------------------- ------------------------------------------------
c) Price(s) and volumes(s) 2022 LTIP Award
Price Volume
Nil 40,261
-------
2021 DBP Award
Price Volume
Nil 17,381
-------
----------------------------- ------------------------------------------------
d) Aggregated information Awards granted over 57,642 shares in
* Aggregate volume total
N/A
* Price
----------------------------- ------------------------------------------------
e) Date of the transaction 2022-04-29
----------------------------- ------------------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- ------------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Madduri Rao
----------------------------- -----------------------------------------
2. Reason for the notification
------------------------------------------------------------------------
a) Position/status Chief Medical Officer
----------------------------- -----------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------------
3. Details of the Issuer
------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- -----------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- -----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- -----------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan. No consideration was paid for
the grant of awards.
----------------------------- -----------------------------------------
c) Price(s) and volumes(s) 2022 LTIP Award
Price Volume
Nil 28,318
-------
2021 DBP Award
Price Volume
Nil Nil
-------
2022 RSU Award
Price Volume
Nil 31,818
-------
----------------------------- -----------------------------------------
d) Aggregated information Awards granted over 60,136 shares in
* Aggregate volume total
N/A
* Price
----------------------------- -----------------------------------------
e) Date of the transaction 2022-04-29
----------------------------- -----------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- -----------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Jason Slingsby
----------------------------- ------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------------
a) Position/status Chief Business Officer
----------------------------- ------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- ------------------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration
was paid for the grant of awards.
----------------------------- ------------------------------------------------
c) Price(s) and volumes(s) 2022 LTIP Award
Price Volume
Nil 36,466
-------
2021 DBP Award
Price Volume
Nil 15,458
-------
----------------------------- ------------------------------------------------
d) Aggregated information Awards granted over 51,924 shares in
* Aggregate volume total
N/A
* Price
----------------------------- ------------------------------------------------
e) Date of the transaction 2022-04-29
----------------------------- ------------------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- ------------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Matthew Treagus
----------------------------- ------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------------
a) Position/status Chief Information Officer
----------------------------- ------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- ------------------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration
was paid for the grant of awards.
----------------------------- ------------------------------------------------
c) Price(s) and volumes(s) 2022 LTIP Award
Price Volume
Nil 38,501
-------
2021 DBP Award
Price Volume
Nil 5,314
-------
----------------------------- ------------------------------------------------
d) Aggregated information Awards granted over 43,815 shares in
* Aggregate volume total
N/A
* Price
----------------------------- ------------------------------------------------
e) Date of the transaction 2022-04-29
----------------------------- ------------------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- ------------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Natalie Walter
----------------------------- ------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------------
a) Position/status General Counsel
----------------------------- ------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- ------------------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration
was paid for the grant of awards.
----------------------------- ------------------------------------------------
c) Price(s) and volumes(s) 2022 LTIP Award
Price Volume
Nil 32,268
-------
2021 DBP Award
Price Volume
Nil 14,008
-------
----------------------------- ------------------------------------------------
d) Aggregated information Awards granted over 46,276 shares in
* Aggregate volume total
N/A
* Price
----------------------------- ------------------------------------------------
e) Date of the transaction 2022-04-29
----------------------------- ------------------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- ------------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Alexander Lewis
----------------------------- -----------------------------------------
2. Reason for the notification
------------------------------------------------------------------------
a) Position/status Chief of Staff
----------------------------- -----------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------------
3. Details of the Issuer
------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- -----------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- -----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- -----------------------------------------
b) Nature of the Grant of award over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan. No consideration was paid for
the grant of awards.
----------------------------- -----------------------------------------
c) Price(s) and volumes(s) 2022 RSU Award
Price Volume
Nil 9,243
-------
----------------------------- -----------------------------------------
d) Aggregated information 9,243
* Aggregate volume N/A
* Price
----------------------------- -----------------------------------------
e) Date of the transaction 2022-04-29
----------------------------- -----------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- -----------------------------------------
-Ends-
For further information, please contact: Oxford Biomedica plc: Tel: +44 (0)1865 783 000 Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.
Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector(R) platform, which the Group leverages to develop product candidates in-house, before seeking partners to take the products into clinical trials.
Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a new US based subsidiary AAV manufacturing and innovation business, based near Boston, US.
Oxford Biomedica employs more than 940 people. Further information is available at www.oxb.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHUPUCGAUPPGQW
(END) Dow Jones Newswires
May 03, 2022 12:18 ET (16:18 GMT)
1 Year Oxford Biomedica Chart |
1 Month Oxford Biomedica Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
